Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Combatir el Alzheimer a través del sueño y el ejercicio (CASE)

23 de octubre de 2026 actualizado por: Azizi Seixas, University of Miami

Combatir el Alzheimer a través del sueño y el ejercicio (CASE)

The Combating Alzheimer's through Sleep and Exercise (CASE) study is an exploratory, hypothesis-generating trial designed to: (1) assess whether improvements in sleep are associated with improvements in cognitive performance and cardiovascular and metabolic health; (2) evaluate the effects of structured, moderate-level aerobic and anaerobic exercise on cognitive performance and cardiovascular and metabolic health; (3) examine the combined, potentially synergistic effects of both interventions on cognitive performance and cardiovascular and metabolic health; and (4) investigate the role of light exposure as a potential modulator of sleep parameters.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Debbie Chung, PhD
  • Número de teléfono: 3052431301
  • Correo electrónico: dxc1729@miami.edu

Ubicaciones de estudio

    • Florida
      • Miami, Florida, Estados Unidos, 33136
        • Reclutamiento
        • University of Miami Hospitals
        • Contacto:
        • Investigador principal:
          • Azizi A Seixas, PhD
        • Sub-Investigador:
          • Alberto Ramos, MD
        • Contacto:
          • Debbie Chung, PhD
          • Número de teléfono: 3052431301
          • Correo electrónico: dxc1729@miami.edu
        • Sub-Investigador:
          • Debbie Chung, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

55 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Aged 55-80 years at the time of the screening visit
  2. Able to ambulate safely and independently
  3. Able to safely perform moderate-intensity exercise as per the Physical Activity Readiness Questionnaire (PAR-Q, a validated exercise readiness questionnaire)
  4. Able to wear and use Fitbit wristwatch and/or the Elemind Neuromodulation headband and Lys devices
  5. Able to operate a digital device like mobile phone or computer
  6. Able and willing to provide venous blood samples
  7. Able to understand and speak English (our AR-based MCI diagnosis tool does not yet have capacity for other languages)
  8. Able to self-report a history of cognitive changes or impairment
  9. Be cognitively able (including those with and without MCI) and willing to provide informed consent
  10. Body weight <400 pounds (<181.4kg) in order to safely operate the NuStep T4r Recumbent Stepper stationary bicycle

Exclusion Criteria:

  1. Severe mobility limitations that prevent safe participation in moderate exercise protocols
  2. Unstable or uncontrolled medical conditions (e.g., recent cardiovascular event (<6 months), cerebrovascular accident or transient ischemic attack (<6 months), active cancer, or uncontrolled diabetes) that pose safety concerns
  3. Inability to complete intake screening procedures
  4. Severe uncorrected hearing impairment-particularly if it precludes effective utilization of the Elemind Neuromodulation headband-and/or vision impairment that interferes with digital device usage or in-person exercise guidance
  5. Determined to have Alzheimer's/dementia based on performance on the Quick Mild Cognitive Impairment (QMCI).
  6. Inability or unwillingness to learn or engage with digital devices (e.g., smartphone, Fitbit, Elemind, or Lys), even with staff support
  7. Regular pre-study engagement in ≥150 minutes of moderate-level and/or ≥75 minutes of vigorous-level exercise per week based on Fitbit data obtained during the initial seven-day onboarding screening period
  8. Determined to have sufficient sleep, as defined by a sleep efficiency mean of ≥80%) based on Elemind Neuromodulation headband data obtained during the initial seven-day onboarding screening period
  9. Current usage of disease-modifying therapy targeting amyloid (e.g., anti-amyloid monoclonal antibodies) or tau
  10. Body weight ≥400 pounds (≥181.4kg), which would pose a safety risk during the operation of the NuStep recumbent stationary bicycle

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Sleep Only Group

Participants in this group will wear the Elemind headband 3-4 times weekly for 8 weeks.

The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm.

Comparador activo: Exercise Only Group

Participants in this group will participate in a structured, on-site, twice a week exercise program for 60 minutes/session for 8 weeks (16 total sessions). Each exercise session is comprised of 60 minutes, including 10 minutes of warm-up, 20 minutes of cardiovascular exercise on a stationary bike, 20 minutes of resistance training (1 day of upper body focus, 1 day of lower body focus each week), and 10 minutes of cooling off).

Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks.

Comparador activo: Exercise and Sleep Group

Participants in this group will take part in the on-site, structured exercise program twice per week for 8 weeks in additional to wearing the Elemind headband 3-4 times per week for 8 weeks.

The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm.

Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Glycated Hemoglobin (HbA1c) Levels
Periodo de tiempo: Up to Week 8

Measured from blood sample

Up to Week 8
Total Cholesterol Levels
Periodo de tiempo: Up to Week 8

Measured from blood sample

Up to Week 8
Triglycerides Levels
Periodo de tiempo: Up to Week 8

Measured from blood sample

Up to Week 8
High-sensitivity C-reactive protein (hs-CRP) Levels
Periodo de tiempo: Up to Week 8

Measured from blood sample

Up to Week 8
Low-Density Lipoprotein (LDL) Levels
Periodo de tiempo: Up to Week 8

Measured from blood sample

Up to Week 8
C-Peptides
Periodo de tiempo: Up to Week 8

Measured from blood sample

Up to Week 8
High-Density Lipoprotein (HDL) Levels
Periodo de tiempo: Up to Week 8

Measured from blood sample

Up to Week 8
Cognitive Function
Periodo de tiempo: Up to 8 weeks

Cognitive function gauged from Altoida's Digital Neuro-Signatures

Up to 8 weeks
Insulin Levels
Periodo de tiempo: Up to 8 weeks

Measured from blood sample

Up to 8 weeks
Neurofilament light chain
Periodo de tiempo: Up to Week 8

Measured from blood sample

Up to Week 8

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Total Sleep Duration
Periodo de tiempo: Up to Week 8

Measured from Elemind

Up to Week 8
Slow Wave Sleep Duration
Periodo de tiempo: Up to Week 8

Measured from Elemind

Up to Week 8
%Slow-wave Sleep
Periodo de tiempo: Up to Week 8

Measured by Elemind headband

Up to Week 8
Rapid Eye Movement Duration
Periodo de tiempo: Up to Week 8

Measured by Elemind headband

Up to Week 8
%REM
Periodo de tiempo: Up to Week 8

Measured by Elemind headband

Up to Week 8
Light Non-Rapid Eye Movement Duration
Periodo de tiempo: Up to Week 8

Measured by Elemind headband

Up to Week 8
%Light Non-Rapid Eye Movement Sleep
Periodo de tiempo: Up to Week 8

Measured by Elemind headband

Up to Week 8
Sleep Efficiency
Periodo de tiempo: Up to Week 8

Measured by Elemind headband

Up to Week 8
Sleep Onset Latency
Periodo de tiempo: Up to Week 8

Measured by Elemind headband

Up to Week 8
Restlessness (Restless Bouts/Hour during Sleep)
Periodo de tiempo: Up to Week 8

Measured by Elemind headband

Up to Week 8

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Light Exposure
Periodo de tiempo: Up to Week 8

Measured by LYS Device

Up to Week 8
Psychosocial Metrics
Periodo de tiempo: Up to Week 8

Measured by Questionnaires

Up to Week 8

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Azizi A Seixas, PhD, University of Miami

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de marzo de 2023

Finalización primaria (Estimado)

30 de diciembre de 2028

Finalización del estudio (Estimado)

30 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

19 de abril de 2021

Primero enviado que cumplió con los criterios de control de calidad

19 de abril de 2021

Publicado por primera vez (Actual)

22 de abril de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

27 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

23 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir